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                                                ABSTRACT 
Title: Magnesium sulphate added as an adjuvant to intrathecal  Bupivacaine in 
patient with mild pregnancy induced hypertension undergoing caesarean section  
Author: prof. P.S. Shanmugam M.D.D.A 
Back ground: Adequate analgesia following caesarean section decreases 
Morbidity, Ambulation, Improve  patient outcome and facilitate care of the 
newborn baby .Intrathecal Magnesium an NMDA antagonist has been shown to 
prolong analgesia without significant side effect in healthy parturients. we 
therefore studied the effect of adding intrathecal Magnesium sulphate to 
Bupivacaine , Fentanyl in patient with mild pregnancy induced hypertension 
undergoing caesarean section.  
Materials and Methods: After obtaining ethical committee approval from 
Govt. Kilpauk medical college ,60 patients with ASA I &II between the age 
group of 18 -35 undergoing elective caesarean section under spinal anesthesia 
were randomly divided in to three groups. 
Group C –Control group, (N=20) patients 0.5% 2cc (10mg) Bupivacaine +0.6cc 
normal saline  
Group F-Fentanyl group, (N=20) patients 0.5% 2cc (10mg) Bupivacaine+0.5cc 
(25micgm) Fentanyl+0.1cc normal saline 
Group M -Magnesium sulphate group, (N=20) patients 0.5% 2cc (10mg) 
Bupivacaine+0.5cc (25micgm) Fentanyl+0.1cc 50% (50mg) magnesium 
sulphate. 
Onset , Duration and recovery of sensory and motor block duration of spinal 
anesthesia, APGAR score and post operative analgesia duration were studied. 
Results: Onset of sensory and motor blockade was delayed in the magnesium 
sulphate group duration of spinal anesthesia and motor block duration is 
prolonged in Magnesium sulphate group.(189.40 minutes) post operative 
analgesia was significantly prolonged in the Magnesium sulphate group when 
compared to control group(403.65vs 222.45minutes) hemodynamic parameter 
at 1,5,10,15,20,30 min were evaluated. 
Conclusion: There is delay in onset of sensory and motor blockade with use of 
Magnesium sulphate. However there is prolonged motor blockade and duration 
of analgesia overlaps well in to the post operative period .This is beneficial for 
the patient for post operative analgesia. APGAR Score not affected between the 
groups. 
Key words: Fentanyl, Magnesium sulphate, Bupivacaine, Pregnancy induced 
hypertension 
 
INTRODUCTION 
 
 Spinal anesthesia was first performed by August Bier on 16th August 
1898 when he injected 3ml of 0.5% cocaine intrathecally. Spinal Anesthesia is 
simple, easy to perform and has got a definite endpoint. It requires a small dose 
of local anaesthetic drugs produces profound sensory and motor blockade. Ever 
since the introduction of local anaesthetic drugs diverse classes of drugs such 
as epinephrine, Opioids, Clonidine, Neostigmine, Ketamine and 
Benzodiazepines have been added as adjuvants to local anaesthetics in an 
attempt to prolong analgesia and reduce the incidence of side effects. 
 Magnesium has been called “Nature’s physiological calcium channel 
Blocker”.Parenteral magnesium has been used for many years on an empirical 
basis for intraoperative and postoperative analgesia. Although systemic 
magnesium decreases postoperative Opioid requirements, its intrathecal use has 
not been evaluated clinically. However, it has been safely used in humans and 
its safety profile has been documented in experimental studies. 
 In 1906, Haubold and Meltzer showed that intrathecal administration of 
Magnesium Sulphate produces spinal anesthesia that includes profound motor 
and sensory blockade without any permanent untoward effects. 
 In this prospective randomized double blind controlled study, we 
evaluated the effect of adding intrathecal Magnesium Sulphate to Bupivacaine 
and Fentanyl in patients undergoing elective Caesarean section. 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 To study and compare the effect of added Fentanyl 25 (micro gm) &  
MgSO4 0.1cc 50% (50mg) to 0.5% 2cc(10mg)Bupivacaine, in patients with 
mild gestational hypertension(PIH) undergoing elective Caesarean section 
under spinal anesthesia. 
 To evaluate 
  Onset time of Sensory block 
 Onset time of Motor block 
  Upper level of analgesia 
 Duration of postoperative analgesia 
 Hemodynamic changes 
 
 
 
 
              
 
APPLIED ANATOMY OF PREGNANCY 
VERTEBRAL ANATOMY: 
 In women of child bearing age, the spinal cord terminates as conus 
medullaris  at the level of the lower border of the first lumbar vertebral body. 
The conus medullaris is attached to the coccyx by means of neuro-fibrous band 
called the filum terminale, which is surrounded by the nerves of the lower 
lumbar and sacral roots known as cauda equina. 
 The subarachnoid space located between the pia mater and arachnoid 
mater, contains (1) Cerebrospinal fluid (CSF) (2) spinal nerves (3) Trabecular 
network between the two membranes (4) Blood vessel that supply the spinal 
cord  and (5) The lateral extension of pia mater –the denticulate ligament. 
 
  
 
 
Effect of pregnancy on lumbar spine: Fig A, Non pregnant. B, pregnant there is 
a marked increase in lumbar lordosis and a narrowing of the interspinous space 
during pregnancy.  
The normal anatomic changes of pregnancy affect the use of neuraxial 
technique. Uterine enlargement and venacaval compression result in 
engorgement of epidural veins .The enlarged epidural veins also may displace 
cerebrospinal fluid(CSF) from the thoracolumbar region of the  subarachnoid 
as does the greater intra abdominal pressure of pregnancy. This displacement of 
CSF and lower specific gravity of CSF, partly  explains lower dose required for 
spinal anesthesia in pregnant patients.  
 The hormonal changes of pregnancy affect the perivertebral  
ligamentous structures , including ligamentum flavum. The ligamentum flavum 
feels less dense and softer in pregnant women than in non pregnant. 
 Achieving flexion of the lumbar spine is difficult for pregnant women. 
Progressive accentuation of lumbar lordosis alter the relationship of surface 
anatomy to the vertebral coloum. The changes that may occur  in pregnancy are 
1.  A pregnant women pelvis rotates on the long axis of the spinal column, 
thus the line joining the iliac crest assume a more cephalad  relationship 
to the vertebral column. 
2.  There is less space between adjacent lumbar spinous  processes during 
pregnancy. It may be more difficult to use the midline approach  to 
identify the epidural or subarachnoid space in pregnant women. 
3. MRI imaging has shown  that the apex of the lumbar lordosis  is shifted 
caudal during pregnancy, and the typical thoracic  kyphosis in women is 
reduced during pregnancy. These changes may influence the spread of 
intrathecal anesthetic solution in supine patient 
 
 
 
 
 
 
 
 
Pelvic widening and resultant head-down tilt in the lateral position during 
pregnancy 
 
 
 
Anatomical changes in respiratory system: 
 The thoracic cage increases in circumference by 5 to 7 cm during 
pregnancy because of increases in both the anteroposterior and transverse 
diameters.
 
 Flaring of the ribs, which begins at the end of the first trimester, 
results in an increase in the sub costal angle from 68.5 to 103.5 degrees at term. 
The vertical measurement of the chest decreases by as much as 4 cm, which 
results from the elevated position of the diaphragm. 
 Capillary engorgement of the nasal and oropharyngeal mucosae and 
larynx begins early in the first trimester and increases progressively throughout 
pregnancy. Nasal breathing commonly becomes difficult, and epistaxis may 
occur because of nasal mucosal engorgement. 
 Airway conductance increases, indicating a dilation of the larger airways 
below the larynx. Factors contributing to airway dilation include the direct 
effects of progesterone, cortisone, and relaxin.  
Anatomical changes in Gastrointestinal system: 
 The stomach is displaced upward toward the left side of the diaphragm 
during pregnancy, and its axis is rotated approximately 45 degrees to the right 
from its normal vertical position. The altered position of the stomach displaces 
the intra abdominal segment of the esophagus into the thorax . This causes a 
reduction in tone of the lower esophageal high-pressure zone (LEHPZ), which 
normally prevents the reflux of gastric contents. This displacement of the 
esophagus also prevents the rise in lower esophageal tone that normally 
accompanies an increase in intragastric pressure (IGP). Progestins also may 
contribute to a relaxation of the LEHPZ. IGP is elevated during the last 
trimester in all pregnant women.
 
 These anatomical changes predispose to 
increased risk of aspiration. 
Feto-placental unit: 
 The placenta is composed of both maternal and fetal tissues that consist 
of a basal and a chorionic plate. It is a semi permeable membrane that provides 
an interface for the maternal and fetal circulation. The intervillous space 
separates the plates and is subdivided by decidual tissue. Chorionic villi and 
spiral arteries protrude into this intervillous space. Maternal blood flows into 
the intervillous space from the spiral artery while placental transfer from the 
mother to the fetus occurs. Approximately 80% of the uterine blood flow 
passes through the intervillous space. 
 Oxygenated blood leaves the placenta through fetal umbilical vein, 
enters the liver where flow divides between portal sinus and ductus venosus 
then empties into IVC. Inside the fetal heart, blood enters the right atrium 
through foramen ovale, where most of the blood is directed into left atrium and 
left ventricle, and then enters aorta. Blood is then sent to the brain and 
myocardium. Deoxygenated blood returning from lower extremities and SVC 
is preferentially directed into right ventricle and pulmonary trunk, majority of 
blood passes through ductus arteriosus into descending aorta. Blood returns to 
the placenta through umbilical arteries for gas and nutrient exchange. Fetal 
blood flow is approximately 75 ml /kg/min, a rate far less than maternal flow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPLIED PHYSIOLOGY 
PHYSIOLOGIC CHANGES OF PREGNANCY: 
 Maternal physiologic changes in pregnancy occur as a result of 
hormonal alterations, mechanical effects of the gravid uterus, increased 
metabolic and oxygen requirements, metabolic demands of the fetoplacental 
unit, and hemodynamic alterations associated with the placental circulation.  
Cardiovascular system:  
 Cardiac output increases during pregnancy to meet the physiological 
demand. Increase in cardiac output is due to an increase in both stroke volume 
and heart rate, the more important factor is stroke volume, which increases by 
20% to 50% at term. 
Diastolic blood pressure falls to a greater degree than does systolic 
blood pressure. The decreased diastolic blood pressure is consistent with 
changes in systemic vascular resistance, which falls during early gestation, 
reaches its nadir (i.e., a 35% decline) at 20 weeks gestation, and rises during 
late gestation. However, systemic vascular resistance remains approximately 
20% below the nonpregnant level at term. The decreased systemic vascular 
resistance results from the development of a low resistance vascular bed (i.e., 
the intervillous space) as well as vasodilation caused by prostacyclin, 
estrogens, and progesterone. Compression of the aorta by the gravid uterus may 
partly account for the greater systemic vascular resistance during the third 
trimester.
Central haemodynamics : 
Parameter Change 
Cardiac output +50% 
Stroke volume +20-30% 
Heart rate +20-50% 
Left ventricular end-diastolic volume Increased 
Left ventricular end-systolic volume No change 
Ejection fraction Increased 
Left ventricular stroke-work index No change 
Pulmonary capillary wedge pressure No change 
Pulmonary artery diastolic pressure No change 
Central venous pressure No change 
Systemic vascular resistance -20% 
Blood Pressure + 15% 
 
Roll over test 
 Comparison of the blood pressure of a pregnant women lying on the 
backside, and excessive increase when she rolls to the supine position indicates 
increased risk of preeclampsia.        
Aortocaval compression: 
 In supine position , gravid uterus compress the aorta and inferior vena 
cava leading to decreased venous return. Venous return occurs primarily by 
diversion of blood through the intraosseous vertebral veins, paravertebral veins, 
and epidural venous plexus. This drop in venous return for which the 
cardiovascular system cannot compensate could result in supine hypotensive 
syndrome . 
 
Respiratory system: 
 Oxygen consumption increases by 30% to 40% during pregnancy. The 
progressive increase in oxygen consumption is caused primarily by the 
metabolic needs of the fetus, uterus, and placenta and secondarily by increased 
cardiac and respiratory work. Carbon dioxide production shows changes 
similar to those of oxygen consumption. 
Wedge 
Respiratory mechanics: 
Parameter Change 
Lung volumes 
Inspiratory reserve volume +5% 
Tidal volume +45% 
Expiratory reserve volume -25% 
Residual volume -15% 
Lung capacities 
Inspiratory capacity +15% 
Functional residual capacity -20% 
Vital capacity No change 
Total lung capacity -5% 
Dead space +45% 
Respiratory rate No change 
Ventilation 
Minute ventilation +45% 
Alveolar ventilation +45% 
 
Hematology:  
 Maternal blood volume begins to increase early in pregnancy as a result 
of changes in osmoregulation and the renin-angiotensin system, causing 
sodium retention and increasing total body water to 8.5 L. By term, blood 
volume increases by up to 45% whereas red cell volume increases by only 
30%. This differential increase leads to the “physiologic anemia” of pregnancy 
with an average hemoglobin and hematocrit of 11.6 g/dL and 35.5%, 
respectively. However, oxygen transport is not impaired by this relative anemia 
because the mother's body compensates for it by increased cardiac output, 
increased PaO2, and a rightward shift in the oxyhemoglobin dissociation curve.   
Hematologic parameters: 
Parameter Change or actual measurement 
Blood volume +45% 
Plasma volume +55% 
Red blood cell volume +30% 
Hemoglobin 11.6 g/dL 
Hematocrit 35.5% 
 
Coagulation changes: 
 A state of hypercoagulability exists in pregnancy, with increased levels 
of most coagulation factors. Pregnancy is associated with enhanced platelet 
turnover, clotting, and fibrinolysis. Thus pregnancy represents a state of 
accelerated but compensated intravascular coagulation. 
 Gastrointestinal system: 
 Progesterone relaxes smooth muscle of the GIT consequently, it impairs 
esophageal and intestinal motility during pregnancy.  
 
 
. 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF PIH 
 Hypertension is the most common medical disorder of pregnancy  
affecting 6%-8% of pregnant women. It results in maternal and fetal 
complication such as preterm birth, intrauterine growth restriction,  fetal and 
maternal death. 
CLASSIFICATION OF HYPERTENSIVE DISORDERS: 
Gestational hypertension:  
 In a woman with no preexisting hypertension or other signs or 
symptoms of preeclampsia, it manifests as elevated blood pressure after 20 
weeks gestation that resolves by 12 weeks postpartum. 
Preeclampsia: 
 It is defined as the new onset of hypertension and proteinuria after 20 
weeks gestation. The National High Blood Pressure Education Program 
(NHBPEP) has recommended that clinicians consider the diagnosis of 
preeclampsia in the absence of proteinuria   when any one of the following are 
present.  
(1) Persistent epigastric or right upper quadrant pain (2) Persistent cerebral 
symptoms (3) fetal growth restriction (4) Thrombocytopenia and (5) 
Elevated serum liver enzymes. 
Eclampsia: 
 The term eclampsia is used when CNS involvement results in the new 
onset of seizures in a woman with preeclampsia 
HELLP syndrome: 
 The term HELLP syndrome refers to the development of Hemolysis, 
Elevated Liver enzymes, and Low Platelets in a women with preeclampsia. 
Chronic hypertension: 
 It is defined as prepregnancy blood pressure levels ≥ 140 mmHg systolic 
or ≥ 90mmHg diastolic or elevated blood pressure that fails to resolve after 
delivery. 
Diagnostic criteria for mild and severe preeclampsia  
Mild preeclampsia Severe preeclampsia 
BP≥140/90mmHg after 20 weeks 
gestation 
Proteinuria(300mg/24 hr or 1+  
result on dipstick specimen) 
BP≥160/110 mmHg 
 
Proteinuria >5 gm/24 hr urine 
specimen (or≥3+ on two random urine 
samples at least 4 hours apart) 
Elevated serum creatinine 
Pulmonary edema  
Oliguria: urine output <500ml in 24 
hrs 
Intrauterine growth restriction 
Headache 
Visual disturbances  
Epigastric or right upper quadrant 
pain due to stretching of Glisson’s 
capsule by hepatic edema 
Impaired liver function  
Thrombocytopenia  
Signs of HELLP syndrome 
 
Risk factors: 
1. Women exposed to chorionic villi for the first time. 
2. Women exposed to a superabundance of chorionic villi, as with twins or 
hydatidiform mole. 
3. Have preexisting vascular disease, Obesity, Diabetes. 
4. Women who are genetically predisposed to hypertension developing 
during pregnancy. 
Prophylaxis and treatment of preeclampsia and eclampsia: 
1) Eclampsia: 
Pritchard regime: 20 ml of 20% MgSO4 slow I.V, followed by 20 ml 
of 50% MgSO4 deep I.M, Thereafter 10 ml of 50% MgSO4 4
th
 hourly till 
24 hours postpartum 
Zuspan’s regime: 4 gm MgSo4 slow I.V followed by 1-2gm/hr I.V 
infusion 
Sibai regime: 6 gm MgSo4 slow I.V followed by 2 gm /hr I.V infusion 
Lytic cocktail or Menon regime: 25 mg Chlorpromazine and 100 mg 
Pethidine  I.V along with 50 mg Chlorpromazine and 25 mg 
Promethazine I.M. subsequently 50 mg Chlorpromazine and 25 mg 
Promethazine I.M. at 4 th hourly intervals for a period upto 24 hrs 100 
mg Pethidine in 500 ml of 10% dextrose at 20 -30 drops/min. 
Lean regime: Diazepam 40 mg I.V and further 40 mg in 500 ml of 5% 
dextrose at 30 drops/min 
Phenytoin therapy:  Initial dose of 10 mg/kg followed by 5mg/kg two 
hours later. Thereafter 200 mg orally after 12 hours continued until 48 
hours. 
 A loading dose of 4-6gm Magnesium Sulphate diluted in 100ml of 
normal saline given over 15min intravenously. Then 2 gm/hr in 100ml of IV 
infusion. (maintain serum levels between 4 and 7mEq/L). 
Intermittent injection: 
 4gm given slow IV followed by 10gm, 5gm in each buttocks as deep IM 
injection. Then every 4 hrs 5gm intramuscularly upto 24hrs after delivery. 
 
 
PATHOGENESIS: 
 Abnormal placentation and failure of normal angiogenesis and 
trophoblastic invasion resulting in hyper response to vasomotor 
stimuli.  
 Widespread endothelial dysfunction and an accentuated systemic 
inflammatory response. 
 Immunological intolerance between maternal and fetoplacental tissues 
and auto antibodies to angiotensin receptor-1 
 Two endogenous antiangiogenic proteins namely Soluble fms-like 
tyrosine kinase-1 and Soluble endoglin are upregulated in 
preeclampsia. 
 Abnormal vasospasm, imbalance of ThromboxaneA2 and 
ProstaglandinI2, altered handling of fatty acids by liver were other 
proposed pathogenesis of PIH. 
  
  
 
 
 
 
 
 
 
 
CLINICAL MANIFESTATIONS: 
Cardiovascular system: 
 Severe vasospasm and greater sensitivity to catecholamines leads 
to hypertension. 
 Severe preeclampsia is a Hyperdynamic state with increased 
cardiac output (CO), increased SVR. 
Hematologic system: 
 Reduction in blood volume causes a greater degree of 
hemoconcentration. 
 Thrombocytopenia is most common hematologic abnormality  
 Preeclampsia is relatively hypercoagulable state 
 Altered relationship between plasminogen activators and inhibitors, with 
a resultant decrease in fibrinolytic activity,   contributes to the 
persistence of fibrin in the renal and placental microvasculature. 
Preeclamptic women have higher concentrations of lipoprotein (a), 
which may be a marker for the severity of disease. Lipoprotein (a) 
enhances blood coagulation by competing with plasminogen for its 
binding sites on fibrin clots and endothelial cells. 
Renal changes: 
 Renal manifestations include persistent proteinuria, changes in GFR and 
Hyperuricemia 
 Oliguria parallels the severity of disease, and persistent oliguria (less 
than 400 mL in 24 hours) requires assessment of volume status. 
Endocrine: 
 In women with preeclampsia, a breakdown of the normal balance 
between vasodilators (e.g., PGI2, nitric oxide) and vasoconstrictors (e.g., 
angiotensin II, TXA2, serotonin, endothelin) occurs. 
 There is also a decrease in plasma renin concentration and a suppression 
of the renin angiotensin-aldosterone system. 
Respiratory system:  
 Pharnygeal and laryngeal edema may make airway management 
difficult, necessitating the use of smaller endotracheal tubes.  
 Decreased colloid osmotic pressure with greater vascular permeability 
increases the risk of pulmonary edema.  
Hepatic changes: 
 Serum transaminase levels frequently increase in patients with mild 
preeclampsia.  
 Epigastric or sub costal pain is an ominous symptom that typically is 
caused by distention of the liver capsule by edema or subcapsular or 
parenchymal bleeding. 
Neurologic changes 
 The classic manifestations of preeclampsia include severe headache, 
visual disturbances, CNS hyper excitability, and hyperreflexia.  
 The occurrence of seizures indicates eclampsia until proved otherwise.  
 The etiology of eclamptic seizures remains unclear. Other proposed 
etiologies for eclamptic seizures include vasospasm, micro infarctions 
and punctate hemorrhages, thrombosis, and cerebral edema. 
Uteroplacental perfusion: 
 Uteroplacental perfusion is decreased in preeclampsia with the potential 
for intrauterine growth retardation 
ANESTHETIC IMPLICATION: 
1.  Altered coagulation precludes regional anesthesia in severe 
preeclampsia 
2.  Exaggerated stress response during laryngoscopy, Hypotension on 
induction due to reduced intravascular volume 
3.  Difficult airway anticipated due to airway edema and capillary 
engorgement 
4.  Risk of aspiration due to delayed gastric emptying time  
5.  Acute pulmonary edema because of increased pulmonary capillary 
permeability 
6.  Strict hemodynamic control and monitoring, FHR monitoring is 
essential 
7.  Magnesium therapy potentiates non depolarising muscle relaxant 
8.  Consider perioperative seizure prophylaxis and pain relief 
PHARMACOLOGICAL CHANGES IN PREGNANCY 
 
PHARMACODYNAMICS OF LA 
 Pregnant women require small doses of local anesthetics due to epidural 
venous engorgement, enhance neural sensitivity to local anesthetics higher PH 
lower bicarbonate and total Carbondioxide content in CSF in women 
undergoing cesarian section. 
PHARMACOKINETICS OF LA: 
 Bupivacaine is the most commonly used local anesthetic in obstetric 
anesthesia because it preserve motor function and is compatible with 
intrathecal opioids. It bound extensively by two proteins, both of which decline 
during pregnancy: (1) alpha-1-acid glycoprotein(AAG), a high-affinity, low-
capacity site, and (2) albumin, a low-affinity, high-capacity site. 
Preeclampsia and LA Drugs  
 In preeclampsia reduced hepatic blood flow, abnormal liver function and 
decreased intravascular volume affect, maternal blood concentration of local 
anesthetics. Long acting amides have a relatively low hepatic extraction ratio, 
changes in liver blood flow in preeclampsia may have less effect on the 
metabolic clearance 
 
Effect on Uterus: 
 Pregnancy may enhance uterine vascular reactivity to local anesthetic 
agents  
Effect on umbilical blood flow: 
 Bupivacaine does not constrict umbilical artery at clinically relevant 
concentration of 0.3-1 mcg/ml. At higher concentration the effect of 
bupivacaine appear to be biphasic.  5-10 mcg/ml produce uterine artery 
constriction more than 125 mcg/ml produce relaxation of artery. 
S/D ratio (systolic peak to diastolic trough of the umbilical artery) in the 
umbilical artery decreases during normal pregnancy and high ratio usually are 
associated with fetal compromise.  
Placental drug transfer: 
Factor affecting placental transfer of drugs include 
1. Physiochemical characteristic of local anesthetic agent 
2. Concentration of free drug in maternal circulation 
3. Permeability of the placenta 
4. Hemodynamic events occurring within the fetal maternal unit 
 
During pregnancy, anatomic adaptations result in substantial (near 
maximal) vasodilation of the uterine spiral arteries, this result in a low-
resistance pathway for the delivery of blood to the placenta. Therefore, 
adequate uteroplacental blood flow depends on the maintenance of a normal 
maternal perfusion pressure. 
 Physical factors (e.g., molecular weight, lipid solubility, degree of 
ionization) affect the placental transfer of drugs and other substances. In 
addition, other factors affect maternal-fetal exchange, including changes in 
maternal and fetal blood flow, placental binding, placental metabolism, 
diffusion capacity, and degree of maternal and fetal plasma protein binding. 
 Lipophilicity, which enhances the central nervous system uptake of 
general anesthetic agents, also heightens the transfer of these drugs across the 
placenta. Fetal acidemia can result in the so-called “ion trapping” of both local 
anesthetics and opioids. 
Molecular size: 
 Compound with a molecular size less than 1000 Daltons crosses the 
placenta easily. 
 
Ionization and lipid solubility: 
 The degree of ionization affect the rate of placental diffusion because 
the unionized molecule is more lipid soluble than ionised molecule. 
Protein binding: 
 Bupivacaine in the maternal plasma is 2 mg/L. bupivacaine are 
approximately 90% bound to maternal plasma proteins,  the free concentration 
of drug available for placental transfer is  0.2 mg/L. At equilibrium, the 
concentration of free drug is equal on both sides of the placenta. However, in 
the fetus, bupivacaine 50% bound to fetal plasma proteins, Total bupivacaine, 
the concentration in fetal plasma is 0.4 mg/L and an F/M ratio of 0.2. 
 Transfer across the placenta may be reported as drug clearance or as a 
ratio that is also referred to as the transfer index used to improve interplacental 
comparisons.  
Teratogenicity: 
 Local anesthetics used during the first trimester of pregnancy  caused 
reversible reduction of cell division in tissue culture. Large multicenter study 
demonstrated that the risk of congenital anomalies in humans was not increased 
by the administration of benzocaine, procaine, tetracaine, or lidocaine during 
early pregnancy. However, a twofold increase in the incidence of congenital 
anomalies was noted in infants whose mothers had received mepivacaine.  
FETUS AND NEWBORN: 
Pharmacokinetics: 
 Local anesthetics, once transferred across the placenta, are distributed in 
the fetus. Factors that influence tissue uptake of the drug include (1) fetal 
plasma protein binding, (2) lipid solubility, (3) the degree of ionization of the 
drug, and (4) hemodynamic changes that affect the distribution of fetal cardiac 
output. 
 The term newborn has the hepatic enzymes necessary for the 
biotransformation of amide local anesthetics. The elimination half-life of these 
drugs is longer in the neonate compared with the adult.
 
The use of mepivacaine 
in obstetric epidural analgesia elimination half-life of the drug in the newborn 
was approximately 9 hours. 
SYSTEMIC TOXICITY: 
 Changes in fetal heart rate (FHR) after administration of local 
anesthetics most often are related to indirect effects such as maternal 
hypotension and uterine hyperstimulation.FHR patterns are not affected by the 
larger doses of local anesthetics required during administration of epidural 
anesthesia for cesarean delivery 
PRETERM FETUS AND NEWBORN: 
 Enhanced drug sensitivity in the preterm newborn: (1) less protein is 
available for drug binding; (2) higher levels of bilirubin are present and may 
compete with the drug for protein binding; (3) greater drug access to the CNS 
occurs because of a poorly developed blood-brain barrier; (4) the preterm 
infant has greater total body water and less fat content; and (5) the preterm 
infant has a decreased ability to metabolize and excrete drugs 
 The placenta efficiently eliminates fetal bilirubin. Thus the 
hyperbilirubinemia of prematurity normally occurs in the postpartum period. 
Bupivacaine has been implicated as a possible cause of neonatal jaundice.
 
 
High affinity of the drug for fetal erythrocyte membranes may lead to a 
decrease in filterability and deformability, which may render red blood cells 
more prone to hemolysis. 
Asphyxia: 
 In asphyxiated preterm fetus , exposure to bupivacaine reduced blood 
flow to vital organs however, fetal heart rate, blood pressure, and acid-base 
measurements did not change Johnson et al.
 
suggested that bupivacaine might 
be preferable to lidocaine in the presence of fetal acidosis because the greater 
maternal protein binding of bupivacaine may limit its placental transfer 
Pharmacokinetic principles 
 Transfer of a drug that is highly protein bound is affected by the 
concentration of both maternal and fetal plasma proteins. The pKa of a drug 
determines the fraction of drug that is nonionized at physiologic pH. Thus, fetal 
acidemia will greatly enhance the maternal-to-fetal transfer (i.e., “ion 
trapping”) of many basic drugs, such as local anesthetics and opioids.  
Factor affecting placental transfer of drug (maternal to fetal) 
 Increased transfer Decreased transfer 
Size-Mol. 
Weight(Dalton) 
<1000 >1000 
Charge of molecule Uncharged Charged 
Lipid solubility Lipophilic Hydrophilic 
PH vs drug Pka Higher proportion of 
un-ionised drug in 
maternal plasma 
Higher proportion of 
ionised drug in maternal 
plasma 
Placental efflux 
transporter 
proteins(e.g.P-
glycoprotein) 
Absent Present 
Binding protein type Albumin (lower 
binding affinity) 
Alpha-1-acid 
glycoprotein(AAG) 
higher binding affinity 
Free (unbound)drug 
fraction 
High Low 
 
Transplacental transfer of anesthetic drug 
Opioids: 
 Opioids have long been the mainstay for systemic pain relief in obstetric 
patients. Safety associated with their use has increased because of a better 
understanding of their pharmacokinetics, improved monitoring, and the ability 
to reverse adverse effects with the antagonist naloxone. 
 Fentanyl and its analogs currently are used extensively as intrapartum 
analgesics. These drugs are administered by the epidural, intrathecal, and 
intravenous routes. Fentanyl has a high degree of lipophilicity and albumin 
binding (84%). Maternal epidural administration of fentanyl results in an F/M 
ratio between 0.37 and 0.57. During early pregnancy, fentanyl is rapidly 
transferred and may be detected not only in the placenta but also in the fetal 
brain. 
Opioid transfer during In Vitro perfusion of the Human Placenta 
 Morphine Meperidine Alfentanil Fentanyl Sufentanil 
Lipid solubility 1.4 39 129 816 1727 
Percent nonionized 
at pH 7.4 
23% 7.4% 
 
89% 8.5% 20% 
Percent protein 
binding 
30% 70% 93% 84% 93% 
Placenta drug ratio 0.1 0.7 0.53 3.4 7.2 
F/M ratio, MTF 0.08 0.27 0.22 0.19 0.14 
F/M ratio, FTM 0.08 0.13 0.11 0.08 0.18 
Minutes to steady 
state 
30 20 20 40-60 40-60 
Clearance index 
MTF 
0.4 0.95 0.75 0.76 0.41 
Clearance index 
FTM 
0.5 0.91 0.78 0.61 0.76 
 
ANESTHETIC DOSE REQUIREMENT: 
 The effects of pregnancy on local anesthetic potency may reflect a 
combined effect of mechanical factors associated with pregnancy (i.e., dilated 
epidural veins decrease the volume of the epidural and subarachnoid spaces) 
and direct effects of hormones, especially progesterone, on the susceptibility of 
nerves to conduction blockade by local anesthetics per se. Hormonal alterations 
are probably the more important of these two factors because greater spread of 
epidural anesthesia occurs during the first trimester of pregnancy, before any 
gross change in vascular dimensions within the epidural or subarachnoid 
spaces. The dosage of local anesthetics should probably be reduced in patients 
in all stages of pregnancy. 
 Pregnancy enhances the spread of hyperbaric local anesthetic solution in 
the subarachnoid space, resulting in a 25% reduction in the segmental dose 
requirement (i.e., milligrams of drug necessary to block one spinal segment) in 
term pregnant women. 
 
PHARMACOLOGY OF BUPIVACAINE 
Structure  
 
 It is an amide local anaesthetic first synthesized in Sweden by 
Ekenstam and his colleagues in 1957 and used clinically by  L.J.Telivuo in 
1963. Its molecular weight is 288. 
PHARMACOKINETIC 
 At pH 7.4 only 15% exists in nonionised form. Absorption depends on 
the site of injection, dosage and use of epinephrine. Primarily metabolized by 
the liver and Lung is capable of extracting bupivacaine from circulation. 
Pka                                                              : 8.1 
Protein Binding                                           : 95% 
Lipid solubility                                           : 28 
Volume of distribution                               : 73 litre 
Clearance of drug from plasma                  : 0.471 lit/min 
Elimination half life                                   : 210 min (3.5 hours) 
Onset time                                                  : 5 -7 min 
F/M ratio                                                     : 0.2-0.4 
PHARMACOLOGY OF FENTANYL 
Structure 
 
 Fentanyl is a synthetic phenylpiperidine opioid, of the 4-anilopiperidine 
PHYSICOCHEMICAL PROFILE 
Molecular weight                                         : 528. 29 
PKa                                                               : 8.4 
% unionized at pH 7.4                                  :8.5 % 
% bound to plasma proteins                        : 84 % 
Potency                                                        : 80 >Morphine 
F/M ratio, MTF                                             : 0.19 
F/M ratio, FTM                                            : 0.08 
Placenta drug ratio                                       : 3.4 
Clearance index, MTF                                 : 0.76 
Clearance index, FTM                                 : 0.61 
 Pharmacokinetic Profile 
Volume of distribution at steady state(VDss)         : 335litres 
Clearance                                                                 : 1530 ml/min 
Effect- site equilibration time                                  : 6.8 min 
Hepatic extraction ratio                                           : 0.8-0.1 
Context – sensitive half time (4 hrs infusion)         : 260 mins 
Elimination half time                                              : 3.1 to 6.6 hours 
First pass pulmonary uptake                                   : 75% 
Neuraxial administration 
 The placement of opioids in the subarachnoid space to that opioid 
receptors (principally µ receptors) are present in the substantia gelatinosa of the 
spinal cord. Analgesia produced by neuraxial opioids, in contrast to the 
intravenous administration of opioids or regional anesthesia with local 
anesthetics, is not associated with sympathetic nervous system denervation, 
skeletal muscle weakness, or loss of proprioception. Analgesia is dose related 
(epidural dose is 5 to 10 times the subarachnoid dose) and specific for visceral 
rather than somatic pain 
Pharmacokinetics: 
 Fentanyl has the same baricity as cerebrospinal fluid at room 
temperature and addition to hyperbaric lignocaine or bupivacaine makes the 
solution hyperbaric. On injection into subarachnoid space, fentanyl mixes with 
CSF and attaches itself to spinal opioid receptors. Protein binding of drug in the 
CSF is negligible and the concentration of opioid in the CSF is thus free drug 
concentration. CSF dynamics do not provide any means of drug removal. 
Diffusion into the spinal cord and absorption into the blood flowing through 
spinal cord must remove all the fentanyl. This rate determining step of drug 
removal is likely to be the rate constant for fentanyl transfer from CSF to spinal 
cord and this rate constant is directly related to lipophilicity. Fentanyl can also 
migrate from the CSF into epidural vascular compartment via the duramater. 
However details of systemic pharmacokinetics of fentanyl are not known. Once 
in the CSF. fentanyl like other opioids, spreads rostrally. Because of the high 
affinity of fentanyl with binding sites in the lipid-rich Spinal cord, only 10% of 
administered dose migrates to cervical region. 
Application 
 Intrathecal fentanyl is usually combined with local anaesthetics for 
Perioperative  anesthesia and analgesia particularly in obstetrics. Fentanyl 
administration intrathecally provides more intense and complete analgesia at 
rest, at a lower dose requirement when compared to the epidural or intravenous 
routes. 
Side effects of intrathecal fentanyl 
 The four classic side effects of neuraxial opioids are pruritus, nausea and 
vomiting, urinary retention, and depression of ventilation.  
 Pruritus is the most common side effect (often localized to face, neck, 
upper thorax) of neuraxial opioids. Pruritus induced by neuraxial opioids is not 
due to histamine release but is likely due to the cephalad migration of the 
opioid in CSF and its subsequent interaction with opioid receptors in the 
trigeminal nucleus. 
Depression of Ventilation 
 The most serious side effect of neuraxial opioids is depression of 
ventilation, which may occur within minutes of administration or may be 
delayed for hours. The incidence of ventilatory depression requiring 
intervention after conventional doses of neuraxial opioids is about 1%,  
 
MAGNESIUM 
Chemical structure of Magnesium 
 
Magnesium was discovered in 1755 by Sir Humpry Davy. Magnesium 
is the fourth plentiful cation in the body and second most abundant intracellular 
cation after potassium. It is a cofactor in hundreds of enzymatic reactions. It is 
a natural calcium antagonist. 
Normal physiology: 
Magnesium is a bivalent cation with atomic weight of 24.312. Human 
body contains one mole (24 gms) of magnesium of which 60% is present in 
bones, 20% is in muscles, 20% is in soft tissues. Only 1% of total body 
magnesium is present extracellularly. 
Intracellular magnesium exists largely (90% ) in bound form in ATP 
molecules of cytoskeleton (nucleus, mitochondria & reticulum). Only a small 
portion ( 5 – 14% ) remains as ionized form within the cell. 
Properties of Magnesium: 
1.  Magnesium intervenes in the activation of Ca ATPase & Na- K ATPase 
involved in transmembrane ion exchange. It acts as a stabilizer of cell 
membrane and intracytoplasmic charges. 
2.  Magnesium has antagonist action on L type calcium channels. It inhibits 
Ca inflows into the cell and outflow of Ca from sarcoplasmic reticulum. 
3.  Magnesium has antagonist effect on N-methyl D-aspartate receptors in 
nervous system. 
4.  Intracellular ionized magnesium is involved in phosphorylation & is 
necessary for activation of hundreds of enzymatic reactions concerning 
ATP. 
Normal serum concentration: 
1.6 to 2.6 mEq /L 
Pharmacological Effects: 
Cardiovascular system: Magnesium causes vasodilatation and may cause 
hypotension at high doses. It slows the rate of SA node impulse formation and 
prolongs SA node conduction time, the PR interval and AV nodal effective 
refractory period. Magnesium attenuates both vasoconstrictor and 
arrythmogenic actions of adrenaline. 
Respiratory system: Magnesium is an effective bronchodilator and attenuates 
hypoxic pulmonary vasoconstriction. 
Central nervous system: Magnesium is a CNS depressant and exhibits 
anticonvulsant properties. High concentrations inhibit catecholamine release 
from adrenergic nerve terminals and adrenal medulla. 
Gastrointestinal system: Magnesium sulphate acts as a antacid when 
administered orally. 
Genito urinary system: Magnesium has renal vasodilator and diuretic effect. 
Toxicity / side effects: 
 Minor side effects include warmth, flushing, nausea, headache and 
dizziness. Dose related side effects include somnolence, areflexia, AV and 
intraventricular conduction disorders, progressive muscle weakness, and 
cardiac arrest. 
USES: 
1)  Magnesium sulphate has a tocolytic effect at serum levels of 8-
10mEq/L. 
 Loading dose of 4-6gm over 20min intravenously, then after the 
contraction ceases maintenance is done using 2-4gm per hour intravenously for 
12-24 hours. 
2)  Magnesium sulphate is used in the dose of 50 mg intrathecally for 
potentiation of opioid analgesia. 
3)  To reduce the stress response during intubation, magnesium sulphate is 
used in the dosage of 30-50mg/kg. intravenously. 
4)  Hypomagnesemia: in case of mild deficiency 1gm every 6 hours for    
4 doses, in severe cases 1-5gms (2 – 10ml of 50% solution) in divided 
doses, repeated until the serum levels are normal. 
PRECAUTIONS: 
 During MgSO4 therapy monitor-urine output, respiratory rate, knee jerk. 
Effect of increasing plasma magnesium level 
Plasma magnesium (MEq/L) Effects 
1.5-2.0 Normal plasma level 
4.0-8.0 Therapeutic range 
5.0-10 Electrocardiographic changes(PQ 
interval prolonged, QRS complex 
widens)  
10-12 Loss of deep tendon reflexes 
15-20 Sinoatrial  and atrioventricular block, 
Respiratory paralysis 
25 Cardiac arrest 
 
 
REVIEW OF LITERATURE 
1) Comparison of intrathecal magnesium, fentanyl, or placebo 
combined with bupivacaine 0.5% for parturients undergoing 
elective cesarean delivery Unlugenc and Ozalevli et al in march 2009 
conducted a prospective, randomized, double-blind study to investigate 
the sensory, motor, and analgesic block characteristics of intrathecal 
magnesium 50 mg compared with fentanyl 25 μg and saline when added 
to 0.5% bupivacaine. METHOD : 90 ASA I and II healthy parturients 
undergoing elective cesarean section were included in the study. Onset 
and duration of sensory and motor block, maximal sensory block height, 
the time to reach the maximal dermatomal level of sensory block, and 
the duration of spinal anesthesia were recorded. CONCLUSION : They 
concluded that in patients undergoing cesarean section with spinal 
anesthesia, the addition of magnesium sulfate (50 mg) intrathecally to 
10 mg of spinal bupivacaine (0.5%) did not shorten the onset time of 
sensory and motor blockade or prolong the duration of spinal anesthesia, 
as seen with fentanyl. ( Acta Anes Scand 2009: 53 : 346-353) 
2)  Combined intrathecal and epidural magnesium sulphate 
supplementation of spinal anesthesia to reduce post-operative 
analgesia requirements R.Arcioni et al in 2007 conducted a 
prospective , randomized, double blind, controlled study in 120 ASA I 
and II patients coming for lower limb orthopedic surgery. METHOD : 
Patients were randomly divide into  
4 groups assigned to receive intrathecal magnesium sulphate, epidural 
magnesium sulphate, combined intrathecal and epidural magnesium 
sulphate or spinal anesthesia alone. Post-operative morphine 
consumption was assessed in all patients using PCA.  
CONCLUSION : In patients undergoing orthopedic surgery, supplementation 
of spinal anesthesia with combined intrathecal and epidural magnesium 
significantly reduces the post-operative analgesic requirements. (Acta Anes 
Scand. 2007 ; 51(4): 482-489 ).  
3) Intrathecal Magnesium Prolongs Fentanyl Analgesia Ashokumar 
Buvanendran et al in 2002 were one of the first to administer 
magnesium intrathecally in humans. They conducted a prospective 
randomized controlled trial in 52 healthy parturient mothers 
requiring labour analgesia. 
METHOD: Patients were randomized to receive either intrathecal fentanyl 25 
μg plus saline or fentanyl 25 μg plus magnesium sulfate 50 mg as part of a 
combined spinal-epidural technique. The duration of analgesia of the 
intrathecal drug combination was defined by the time of patient request for 
additional analgesia. RESULT: There was significant prolongation in the 
median duration of analgesia in the magnesium plus fentanyl group compared 
with the fentanyl alone group.  
 
CONCLUSION: They concluded that intrathecal magnesium prolongs spinal 
opioid analgesia in humans and suggest that the availability of an intrathecal 
Nmethyl-D-aspartate antagonist could be of clinical importance for pain 
management.  
(Anesth Analg 2002;95:661-666 ). 
 
4)  Intrathecal versus intravenous fentanyl for supplementation of 
subarachnoid block during cesarean delivery Sahar and Marie et al in 2002 
conducted a randomized study in 48 healthy parturient patients undergoing 
elective cesarean section. One group received 12 mg of hyperbaric bupivacaine 
plus 12.5 μg of fentanyl intrathecally. Another group received 12 mg of 
hyperbaric bupivacaine intrathecally and 12.5 μg of fentanyl intravenously 
immediately after spinal. They found that additional intravenous fentanyl was 
needed in IV fentanyl group and incidence of hypotension and use of ephedrine 
was more in IV fentanyl group. The time to the first request for postoperative 
analgesia was significantly longer in the intrathecal fentanyl group than in the 
IV fentanyl group. They concluded that supplementation of spinal bupivacaine 
anesthesia for cesarean delivery with intrathecal fentanyl provides a better 
quality of anesthesia and is associated with a decreased incidence of side 
effects as compared with supplementation with the same dose of IV fentanyl 
(Anesth Analg 2002;95:209-213). 
5)  The effect of adding intrathecal magnesium sulphate to morphine 
for postoperative analgesia after caesarean section Khemakhem K et 
al in 2006 conducted a prospective, randomized, double blind, 
controlled study to know the effect of intrathecal magnesium sulphate, 
morphine and their association in postoperative analgesia. METHOD: 
97 ASA I and II parturients undergoing cesarean section are randomly 
allocated to 3 groups to receive 0.1 mg of morphine or 100 mg of 
magnesium or both. 
 Postoperative analgesia with the visual analogic score (VAS), analgesic 
requirement, and side effects were recorded. CONCLUSION: The addition of 
intrathecal magnesium sulphate 100 mg to morphine improved quality and 
duration of the postoperative analgesia with a better maternal satisfaction 
without additional side effects. ( Euro Anes 2006 jun; 23: 183-4). 
6)  Magnesium infusion reduces perioperative pain Kara H, Sahin N, 
Ulusan V, Aydogdu T in 2002 conducted a study to determine whether 
perioperative infusion of magnesium would reduce postoperative pain 
and anxiety. METHOD: Twenty-four patients, undergoing elective 
hysterectomy, received a bolus of 30 mg/kg magnesium sulphate or the 
same volume of isotonic sodium chloride solution intravenously before 
the start of surgery and 0.5 g/hr infusion for the next 20 hr. 
Intraoperative and postoperative analgesia were achieved with fentanyl 
and morphine respectively. Patients were evaluated pre- and 
postoperatively for anxiety. CONCLUSION: Continuous magnesium 
infusion, including the pre-, intra-, and postoperative periods reduces 
analgesic requirements and reduces the anxiety of the patients. ( Eur J 
Anesthesiol. 2002 Jan;19(1):52-6 ). 
7)  Role of magnesium sulfate in postoperative analgesia Tramer MR et 
al in 1996 conducted one of the earliest studies to demonstrate the anti 
nociceptive characteristics of magnesium. METHOD In a randomized 
double – blind study, they included 42 ASA I and II patients undergoing 
abdominal hysterectomy. Study group received 15 ml of 20% 
magnesium before start of surgery and an infusion of 2.5 ml/hr for next 
20 hrs. Control group received same amount of normal saline. 
Maximum expiratory flow (peak flow), pain at rest and during peak flow 
and discomfort were evaluated up to the 48th postoperative hour and 1 
week and 1 month after surgery. Insomnia was evaluated after the first 
and second postoperative nights. CONCLUSION: They concluded that 
the perioperative application of magnesium sulphate is associated with 
smaller analgesic requirement, less discomfort, and a better quality of 
sleep in the postoperative period but not with adverse effects.  
(Anaesthesiology;1996:84(2) 340-7). 
 
 
MATERIALS AND METHODS 
Patient selection: 
 After obtaining ethical committee approval from Govt.  Kilpauk 
Medical College. 60 Pregnant women with mild PIH undergoing elective 
Caesarean section ASA I and II between the age group of 18-35 under spinal 
anesthesia were randomly divided into three groups.  
 Minimal fasting period is 8hrs, IV line secured with 18G venflon All 
patients received premedication with Inj. Ranitidine 50mg IV and Inj. 
Metoclopramide 10 mg IV, 10 min before surgery and preloaded with RL 10-
12ml /kg. All patients received 5L of O2 / min through mask throughout 
procedure Patients were treated with titrated doses of  
 Inj. Ephedrine 6mg I.V if systolic BP<90mmhg 
 Inj. Atropine 0.6mg I.V if heartrate <60/min  
After delivery of baby Inj. Oxytocin 10 IU in drip and 10 IU IM given  
INCLUSION CRITERIA EXCLUSION CRITERIA 
ASA I and II Contraindications to spinal anesthesia  
 
Age between 18-35 years  
 
Heart disease 
Mild PIH (BP<160/110mmHg) Fetal distress 
Elective Caesarean Section  Eclampsia 
 Allergy to local anesthetic drugs  
 Seizure disorders 
 Patient with coagulation disorders 
 
GROUPS: 
Group C 
Control group, (N=20) patients 0.5% 2cc (10mg) Bupivacaine + 
0.6cc normal saline. 
Group F:  
Fentanyl (N= 20) patients received 0.5% 2cc Bupivacaine +0.5cc 
(25mic gm) Fentanyl +0.1cc NS. 
Group M: 
MgSO4 group (N=20), 0.5% 2cc Bupivacaine +0.5cc Fentanyl 
+0.1cc 50%(50mg) MgSO4. 
 All patients were monitored with ECG, NIBP, Pulse Oximetry. 
Respiratory rate, urinary output and knee jerk were also monitored. Under 
aseptic precaution patient in right lateral decubitous position by mid line 
approach spinal anesthesia was performed according to the study groups. 
Wedge was placed to prevent decreasing venous return due to aortocaval 
compression. 
The local anesthetic drug prepared by the assistant according to the 
group and given to his performer who injected drug by spinal anesthesia 
without knowing the content of the drug he records his findings needed for the 
study.        
Observation 
The onset of sensory blockade, motor blockade, upper level of 
analgesia, intensity of motor block, two segment regression time, APGAR 
Score, Postoperative analgesia duration and hemodynamic parameters at 
1,5,10,15,20,30 minutes were observed. 
 Motor block was assessed by Bromage motor score and sedation by 
Ramsay sedation score. 
Sensory score: 
Score  response  
0  normal sensation  
1  analgesia (loss of pin prick sensation)  
2  anesthesia (loss of touch sensation)  
 
Bromage motor score 
Grade Response Degree of block 
0 no motor block  nil(0%)  
1 unable to straight leg raise  partial(33%)  
2 unable to flex knee against 
resistance  
almost 
complete(66%)  
3 unable to flex ankle  complete  
 
Ramsay sedation Score: 
Score Response 
1 anxious or restless or both  
2 Co-operative, oriented & tranquil  
3 responds  to  commands 
4 brisk  response  to  stimulus  
5 sluggish  response to stimulus  
6 no response to stimulus  
 
SENSORY BLOCK ONSET TIME 
 Time interval between end of anesthetic injection and appearance of 
cutaneous analgesia in dermatomes    T-12,T-10,T-8,T-6 
DURATION OF MOTOR BLOCK 
 Administration of anesthetic and attainment of grade 0 in Bromage 
motor scale 
DURATION OF ANALGESIA 
 Administration of anesthetic and disappearance of cutaneous level of 
sensation at each dermatomal level 
POST-OP ANALGESIA DURATION 
 Administration of anesthetic and time of analgesic requirement in 
PACU.  
 
 
 
 
 
OBSERVATION AND RESULTS 
 
 
 
 
  
 
 
 
 
 
 
 
 
ANOVA
Sensory block onset time
2.594 2 1.297 16.816 .000
4.318 56 .077
6.912 58
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
Descriptives 
Sensory block onset time 
20 .62 .204 .046 .52 .72 1 1 
20 .54 .123 .028 .49 .60 1 1 
20 1.03 .424 .097 .82 1.23 1 2 
60 .73 .345 .045 .64 .82 1 2 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
Onset and intensity of motor block
.533 2 .267 1.261 .291
12.050 57 .211
12.583 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
Descriptives 
Onset and intensity of motor block 
20 2.15 .489 .109 1.92 2.38 1 3 
20 1.95 .394 .088 1.77 2.13 1 3 
20 2.15 .489 .109 1.92 2.38 1 3 
60 2.08 .462 .060 1.96 2.20 1 3 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
Motor block onset time in min
350.856 2 175.428 101.511 .000
98.506 57 1.728
449.362 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
Descriptives 
Motor block onset time in min 
20 5.350 1.3387 .2993 4.723 5.977 3.0 8.0 
20 3.315 .8707 .1947 2.907 3.723 2.0 5.0 
20 9.150 1.6230 .3629 8.390 9.910 6.5 12.0 
60 5.938 2.7598 .3563 5.225 6.651 2.0 12.0 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
 
 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
Analgesic and motor block duration in min
47626.533 2 23813.267 101.073 .000
13429.400 57 235.604
61055.933 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
 
 
Descriptives 
Analgesic and motor block duration in min 
20 131.90 11.634 2.602 126.45 137.35 110 156 
20 127.60 14.065 3.145 121.02 134.18 100 145 
20 189.40 19.329 4.322 180.35 198.45 156 218 
60 149.63 32.169 4.153 141.32 157.94 100 218 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
Duration of post operative analgesia in min
328401.900 2 164200.950 310.567 .000
30136.700 57 528.714
358538.600 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
  
 
 
 
 
 
 
 
Descriptives 
Duration of post operative analgesia in min 
20 310.80 25.548 5.713 298.84 322.76 262 338 
20 222.45 13.942 3.117 215.93 228.97 198 242 
20 403.65 27.186 6.079 390.93 416.37 371 460 
60 312.30 77.955 10.064 292.16 332.44 198 460 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
BP SYS 1 MIN
115.633 2 57.817 .310 .734
10616.700 57 186.258
10732.333 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
BP SYS 1 MIN 
20 131.55 6.108 1.366 128.69 134.41 122 142 
20 129.80 17.698 3.957 121.52 138.08 90 152 
20 128.15 14.431 3.227 121.40 134.90 98 154 
60 129.83 13.487 1.741 126.35 133.32 90 154 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
BP DIA 1 MIN
141.733 2 70.867 .622 .540
6492.600 57 113.905
6634.333 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
BP DIA 1 MIN 
20 82.00 7.398 1.654 78.54 85.46 66 92 
20 85.10 13.082 2.925 78.98 91.22 60 108 
20 85.40 10.763 2.407 80.36 90.44 60 100 
60 84.17 10.604 1.369 81.43 86.91 60 108 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval 
for Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
BP SYS 5 MIN
511.300 2 255.650 1.526 .226
9550.300 57 167.549
10061.600 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
BP SYS 5 MIN 
20 115.65 13.647 3.052 109.26 122.04 90 146 
20 119.15 14.376 3.215 112.42 125.88 80 142 
20 122.80 10.476 2.343 117.90 127.70 100 146 
60 119.20 13.059 1.686 115.83 122.57 80 146 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval 
for Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
BP DIA 5 MIN
513.100 2 256.550 2.967 .059
4928.550 57 86.466
5441.650 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
BP DIA 5 MIN 
20 71.70 9.804 2.192 67.11 76.29 52 92 
20 74.90 8.955 2.002 70.71 79.09 58 90 
20 78.85 9.115 2.038 74.58 83.12 60 96 
60 75.15 9.604 1.240 72.67 77.63 52 96 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
Ephedrine requirement: 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
Ephedrine requirement in mg
817.600 2 408.800 43.147 .000
540.050 57 9.475
1357.650 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
 
 
 
 
 
 
Descriptives 
Ephedrine requirement in mg 
20 11.15 3.297 .737 9.61 12.69 6 18 
20 17.35 3.407 .762 15.76 18.94 12 24 
20 8.55 2.438 .545 7.41 9.69 6 12 
60 12.35 4.797 .619 11.11 13.59 6 24 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
APGAR 1 min
1.900 2 .950 1.636 .204
33.100 57 .581
35.000 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
APGAR 1 min 
20 6.25 .716 .160 5.91 6.59 5 7 
20 6.65 .933 .209 6.21 7.09 5 8 
20 6.60 .598 .134 6.32 6.88 6 8 
60 6.50 .770 .099 6.30 6.70 5 8 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
 
 
 
 
 
 
 
Univariate Analysis, ANOVA & Two Group T-Test 
 
ANOVA
APGAR 5 min
3.333 2 1.667 2.746 .073
34.600 57 .607
37.933 59
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Descriptives 
APGAR 5 min 
20 8.20 .951 .213 7.75 8.65 6 9 
20 8.20 .768 .172 7.84 8.56 7 9 
20 8.70 .571 .128 8.43 8.97 7 9 
60 8.37 .802 .104 8.16 8.57 6 9 
FENTANYL 
CONTROL 
MgSO4 
Total 
N Mean Std. Deviation Std. Error Lower Bound Upper Bound 
95% Confidence Interval for 
Mean 
Minimum Maximum 
 
DISCUSSION 
  The study was conducted at Govt. Kilpauk Medical College on 60 
pregnant patient with mild PIH ASA I and II undergoing elective Caesarean 
Section under spinal anesthesia after obtaining informed consent. Sensory and 
motor block onset time, upper level of analgesia, Duration of analgesia and 
motor blockade and APGAR score hemodynamics between the groups were 
evaluated. 
 The safety of intrathecal magnesium sulphate administration in humans 
and animals have been established. SIMPSON et al and KROIN et al 
demonstrated in animals by their study that intrathecal magnesium sulphate has 
a safety profile. 
 OZALEVLI et al and BUVENDRAN et al demonstrated no 
deleterious effects in humans on administration of intrathecal magnesium 
sulphate in their study they used 50mg of MgSO4. The dose of magnesium 
sulphate was based on data from a rat model of postoperative pain in which188 
micrograms of intrathecal magnesium sulphate potentiated morphine 
antinociception done by KROIN et al. Based on the relative differences 
between human and rat CSF volume and body weight, the 188 microgram dose 
was conservatively extrapolated to 50 mg for humans. 
 In my study sensory block onset time in magnesium sulphate group is 
(1.03 min) compared to control group (0.54 min) which is statistically 
significant (P value 0.000). Delayed onset of sensory block in magnesium 
sulphate group
12
.
 
 Onset of motor block in magnesium sulphate group is (9.15 min) when 
compared to control group (3.31 min) which is statistically significant (P value 
0.000).
6 
Hence there is a delay in the onset of motor block. 
 Intensity of motor block in Magnesium sulphate group is 2.25 and in 
control group 95 which is statistically less significant (P value0.291).
14 
 Analgesic and motor block duration is prolonged in magnesium sulphate 
group (189.40 min) when compared to control group which is statistically 
highly significant (P Value 0.000)
6,25 
 Fall in blood pressure and requirement of ephedrine is more in the 
control group (17.35 mg) compared to Magnesium sulphate groups (8.55 mg) 
(P value 0.000) highly significant due to high level of blockade
25 
 Sedation score of Fentanyl group is 2.20 compared to control group 
which is statistically significant (P value 0.000).
25 
 Duration of post operative analgesia- Duration is prolonged in 
Magnesium sulphate group 403.65 min when compared with control group 
222.45, statistically highly significant( P value 0.000) 
24,6 
There is no difference in APGAR score 1 min and 5 min between the 
groups ( P value 0.204, 0.073) respectively statistically insignificant.  
3 patients in fentanyl groups complaint of prurities, 2 patients due to 
inadequate blockade converted to GA were excluded from the study.    
  
CONCLUSION 
There is a delay in the onset of sensory and motor blockade with the use 
magnesium sulphate group .However there is prolonged motor blockade and 
duration of analgesia overlaps well into the postoperative period .This is 
beneficial for the patient for post operative analgesia, APGAR score not 
affected between the groups.   
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
1. CHESTNUT’S Obstetric anesthesia principle and practice, fourth 
edition 14-18. 
2.  Williams Obstetrics 22 nd edition 2005,1020-1035. 
3.  SRIVINSKAS E LAURINAITIS R. Use of magnesium in 
anesthesiology. Medicine 2002;38:147-50 
4.  BEGON S, PICKERING G, ESCHALIER A, DUBRAY C. Magnesium 
increases morphine analgesic effects in different experimental models of 
pain. Anaesthesiology 2002;96:627-32. 
5.  KROIN JS, MCCARTHYRJ, VON ROENN N, SCHWAB B, TUMAN 
KJ, IVANKOVICH AD. Magnesium sulphate potentiates morphine 
anti-nociception at spinal level. Anaesth Analg 2000;90:913-7. 
6.  BUVANENDRAN A ET AL., Intrathecal magnesium prolongs fentanyl 
analgesia: a prospective randomized controlled trial. Anaesth Analg 
2002;95: 661-7. 
7.  KOINIG H, WALLNER T,MARHOFER P, ANDEL H, HORAUF K, 
MAYER N. Magnesium sulphate reduces intra and post operative 
analgesia requirements. Anaesth Analg 1998;87:206-10. 
8.  TRAMER MR, SCHENEIDERJ, MARTI RA, KAPLAN R. Role of 
magnesium sulphate in postoperative analgesia. Anaesthesiology 
1996;84:340-7. 
9.  RONALD D .MILLER, Miller’s Anaesthesia, 7th edition, vol 2 : 2422- 
2426. 
 
10. Chanimov M, Cohen ML, Grinspun Y, et al. Neurotoxicity after spinal 
anaesthesia induced by serial injections of magnesium sulphate: an 
experimental study in a rat model. Anaesthesia. 1997;52:223–228. 
11.   KARA H, SAHIN N, ULUSAN V, AYDOGDU T. Magnesium infusion 
reduces postoperative pain. Eur J Anaesthesiol. 2002 Jan;19(1):52-6. 
12.  SAHAR M. SIDDIK-SAYYID, MARIE T. AOUAD, ET AL. 
Intrathecal versus intravenous fentanyl for supplementation of 
subarachnoid block during cesarean delivery. Anesth Analg 
2002;95:209-213. 
13.  BHATIA A, KASHYAP L, PAWAR DK, TRIKHA A. Effect of 
intraoperative magnesium infusion on perioperative analgesia in open 
cholecystectomy. J Clin Anesth. 2004 Jun;16(4):262-5. 
14.  KHEMAKHEM, K.; SMAOUI, M.; GHRAB, B. ET AL .The effect of 
adding intrathecal magnesium sulphate to morphine for postoperative 
analgesia after caesarean section. Eur J Anaesth 2006;23:183-84. 
15.  BIRBICER,H.;AVLAN,D, ET AL. Could adding magnesium as 
adjuvant in caudal anesthesia improve postoperative pain control? 
Pediat Surg Interna 2006;23:195-98. 
16.  ARCIONI,R.; PALMISANI,S.; TIGANO,S.; ET AL. Combined 
intrathecal and epidural magnesium sulphate supplementation of spinal 
anesthesia to reduce postoperative analgesic requirement. Acta Anaes 
Scandi 2007;51(4):482-9. 
17. UNLUGENC,H.; OZALEVLI, M. ET AL. Comparison of intrathecal 
magnesium, fentanyl, or placebo combined with bupivacaine 0.5% for 
parturients undergoing elective cesarean delivery. Acta Anaes Scandi 
2009;53(3)346-53. 
18.  FAWCETT WJ, HAXBY EJ, MALE DA. Magnesium physiology and 
pharmacology. Br J Anaesth 1999;83;302-20. 
19. CHANIMOV M, COHEN MI, GRINSPUN Y ET AL. Neurotoxicity 
after spinal anesthesia induced by serial injection of magnesium 
sulphate. An experimental study in a rat modal. Anaesthesia 
1997;52:223-8. 
20. Brown DL, Spinal, Epidural and Caudal anesthesia, In: Ronald  
D Miller’s Anesthesia, 5th edition Philadelphia, Churchchill Livingstone 
2000; 1491-1508. 
21.  Reynolds FJM, Spinal and epidural block, In: Churchill-Davidson  
HC, 5th edition, Wylie 
22.  Stoelting RK. Opioid Agonists and Antagonists. In: Pharmacology and 
Physiology in Anaesthetic Practice. Philadelphia, Lippincott- Raven 
1999;93-96. 
23. Simpson.Thomas. Intrathecal magnesium sulphate protects the spinal 
cord from ischaemic injury during thoracic aortic cross clamping. 
Anaesthesiology.1994;81(6);1493-98. 
24. M.Ozalevli.T.O.Cetin.T.Guler The effect of adding intrathecal 
magnesium sulphate to bupivacaine and fentanyl spinal anesthesia. Acta 
anesthesiol scand 2005;49;1514-19. 
25. International journal of obstetric Anesthesia, Volume19,Issue 2,April 
2010,pages 161-166. S. Malleswaran, N. Panda ,P. Mathew, R. Bagga. 
26. Wallace DH, Leveno KJ, Cunningham FG, Giesecke A, Shearer VE, 
Sidawi JE. Randomized comparison of general and regional anesthesia 
for cesarean delivery in pregnancies complicated by severe pre-
eclampsia. Obstet Gynecol. 1995;86:193–199. 
27. Karinen J, Rasanen S, Alahuhta S, Jouppila R, Jouppila P. Maternal 
and uteroplacental haemodynamic state in pre-eclamptic patients 
during spinal anaesthesia for caesarean section. Br J 
Anaesth. 1996;76:616–620. 
28. Hood DD, Curry R. Spinal versus epidural anesthesia for cesarean 
section in severely pre-eclamptic patients. 
Anesthesiology. 1999;90:276–282. 
29. Roseag OP, Lui CP, Cicutti NJ, Bragg PR. Perioperative multimodal 
pain therapy for caesarean section: analgesia and fitness for 
discharge. Can J Anesth. 1997;44:803–809 
30. Schobel HP, Fischer  T, Heuszer K, Geiger H, 
Schmieder RE. Preeclampsia : a state of sympathetic overactivity. N 
Engl J Med.1996;335:1480–1485. 
31. Shoebi G, Sadegi M, Firazian A, Tabassomi F. The additional effect of 
magnesium to lidocaine in spinal anaesthesia for caesarean 
section. Int J Pharmacol. 2007;3:425–427 
32. Mageed Nabil A, El-Ghoniemy Yasser F. Intrathecal fentanyl-
magnesium for fast-track cardiac anaesthesia. Eg J 
Anaesth.2005;21:289–293 
33. Marzouk S, El-Hady NA, Lotfy M, Darwish HM. The effect of three 
different doses of intrathecal magnesium sulphate on spinal opioid 
analgesia. Eg J Anaesth. 2003;19:405–409 
34. Chernik DA, Gi1lings D, Laine H, Hendler J, Silver J, 
Davidson AB. Validity and reliability of the observer’s assessment of 
alertness/sedation scale: Study with intravenous midazolam. J Clin 
Psychopharmacol. 1990;10:244–251. 
35. Liu HT, Hillman MW, Liu WH, et al. Modulation of NMDA receptor 
function by ketamine and magnesium. Part 2. Anesth 
Analg.2001;92:1173–1181. 
36. Woolf CJ, Chong MS. Preemptive analgesia-treating postoperative 
pain by preventing the establishment of central sensitization. Anesth 
Analg. 1993;77:362. 
37. Woolf CJ, Thompson SW. The induction and maintenance of central 
sensitization is dependent on N-methyl-D-aspartic acid receptor 
activation; implications for the treatment of post-injury pain 
hypersensitivity states. Pain. 1991;44:293–299. 
38. Ascher P, Nowak L. Electrophysiological studies of NMDA 
receptors. Trends Neurosci. 1987;10:284–288. 
39. Ko SH, Lim HR, Kim DC, Han YJ, Choe H, Song HS. Magnesium 
sulfate does not reduce postoperative analgesic 
requirements. Anesthesiology. 2001; 95:640–646 
40. Duley L, Watkins K. Magnesium sulphate for treatment of 
preeclampsia: a trial to evaluate the effects on women and their 
babies. Contemp Rev Obstet Gynaecol. 1998;10:267–274. 
41. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia 
and eclampsia. Obstet Gynecol. 1998;92:883–889. 
42. Gurkan Y, Toker K. Prophylactic ondansetron reduces the incidence 
of intrathecal fentanyl-induced pruritus. Anesth 
Analg.2002;95:1763–1766. 
43. Takano Y, Sato E, Kaneko T, Sato I. Antihyperalgesic effects of 
intrathecally administered magnesium sulphate in 
rats. Pain.2000;84:175–179. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 MASTER CHART 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
GROUP  C- CONTROL 
 
 
 
GROUP F-FENTANYL 
 
 
 
GROUP M- MgSO4  
 
 
 
